Sustained delivery of commensal bacteria from pod-intravaginal rings.
Topical administration of live commensal bacteria to the vaginal tract holds significant potential as a cost-effective strategy for the treatment of sexually transmitted infections and the delivery of mucosal vaccines. Probiotic-releasing intravaginal rings (IVRs) embody significant theoretical advantages over traditional daily-dosage forms, such as sustained and controlled delivery leading to improved adherence to therapy compared to that of frequent dosing. The conventional IVR designs, however, are not amenable to the delivery of live bacteria. We have developed a novel pod-IVR technology where polymer-coated tablets ("pods") of Lactobacillus gasseri strain ATCC 33323, a commensal microorganism of human origin, are embedded in silicone IVRs. The release rate of bacterial cells is controlled by the diameter of a delivery channel that exposes a portion of the pod to external fluids. In vitro studies demonstrated that the prototype devices released between 1.1×10(7) and 14×10(7) cells per day for up to 21 days in a controlled sustained fashion with stable burst-free release kinetics. The daily release rates were correlated with the cross-sectional area of the delivery channel. Bacteria in the IVR pods remained viable throughout the in vitro studies and formed biofilms on the surfaces of the devices. This proof-of-principle study represents the first demonstration of a prolonged, sustained release of bacteria from an intravaginal device and warrants further investigation of this device as a nonchemotherapeutic agent for the restoration and maintenance of normal urogenital flora.
Department of Chemistry, Oak Crest Institute of Science, Pasadena, California, USA.
Manjula
M
Gunawardana
Madeline
M
Mullen
Jennifer
J
Yoo
Paul
P
Webster
John A
JA
Moss
Marc M
MM
Baum
D000282:Administration, Intravaginal; D003692:Delayed-Action Preparations; D016503:Drug Delivery Systems / Q000379:methods*; D005260:Female; D006801:Humans; D007778:Lactobacillus / Q000502:physiology; D019936:Probiotics / Q000008:administration & dosage*; D014621:Vagina / Q000382:microbiology*
D003692:Delayed-Action Preparations